The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1714
October 28, 2024
View Complete Issue         Table of Contents 2019 
In Brief: FluMist Influenza Vaccine for Self-Administration
Download PDF:   US English
Disclosures & ObjectivesDisclosures & Objectives
Take CME Exam
View Complete Issue
Send Article Feedback
Med Lett Drugs Ther. 2024 Oct 28;66(1714):174-5   doi:10.58347/tml.2024.1714c
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Additional Contributor(s)
  • Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Review the recommendations for use of the FluMist influenza vaccine for self-administration
 Select a term to see related articles  FluMist   influenza   vaccines 

FluMist (AstraZeneca), the live-attenuated intranasal influenza vaccine that has been available for years for administration by a healthcare provider in nonpregnant persons 2-49 years old, has now been approved by the FDA for self- or caregiver-administration. It is expected to be available for such use during the 2025-2026 influenza season.1 FluMist is only available through a healthcare provider this season. It will continue to be available for administration by a healthcare provider in the future.

DOSAGE AND ADMINISTRATION — FluMist is suppled in 0.2-mL single-use intranasal sprayer devices. The vaccine may contain residual amounts of ovalbumin (egg protein) and gentamicin sulfate. A single 0.2-mL dose (0.1 mL in each nostril) is recommended for most patients each season.1

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article